IDH3A and central nervous system cancer: Isocitrate dehydrogenase (IDH)-mutant glioma patients are often diagnosed at a young age (median age of 36 and 38 years for WHO Grades 2/3 and Grade 4, respectively) with a median survival over 12.3 years1–4.